Search

A 60-year-old man with stage 3A lung adenocarcinoma experienced lack of efficacy during treatment with multiple drugs, including cisplatin, paclitaxel, crizotinib, and pemetrexed. He also developed Cytomegalovirus (CMV) tracheobronchitis and neutropenia during his treatment. Despite various therapies, the man ultimately passed away due to massive haemoptysis secondary to CMV tracheobronchitis, highlighting the challenges in managing complex medical conditions. [Extracted from the article]

A 57-year-old non-smoking woman with stage IV lung adenocarcinoma and anaplastic lymphoma kinase (ALK) rearrangement experienced lack of efficacy while being treated with crizotinib. Despite receiving crizotinib for three years, she developed multiple cerebral metastases, prompting a switch to brigatinib. After a year of brigatinib treatment, she developed erythema nodosum on her left elbow and lower limb, which resolved spontaneously after three months. Brigatinib was continued for nearly three years following the switch. [Extracted from the article]

A 50-year-old man with stage IVA salivary gland adenocarcinoma experienced mild nausea and diarrhea while being treated with crizotinib, cisplatin, cyclophosphamide, and doxorubicin. Despite initially tolerating crizotinib, he later showed lack of efficacy with the drug. After trying various treatments, including alectinib, he experienced marked improvement in his condition but eventually opted for hospice care after rapid disease progression. [Extracted from the article]

In a study of 190 patients with hepatocellular carcinoma, two cases were reported where patients exhibited a lack of efficacy during treatment with various drugs. One patient received a combination of folinic-acid, fluorouracil, oxaliplatin, and lenvatinib, while the other patient received crizotinib. Despite the treatments, both patients showed a lack of response and experienced disease progression. These cases highlight the need for further research and alternative treatment options for hepatocellular carcinoma. [Extracted from the article]

In a single center study, 15 patients between the ages of 12 and 28 were described as exhibiting lack of efficacy during treatment for anaplastic large cell lymphoma expressing the anaplastic lymphoma kinase mutation. The patients were initially treated with various drugs including prednisone, vincristine, daunorubicin, asparaginase, cyclophosphamide, cytarabine, mercaptopurine, methotrexate, and vinblastine. Some patients also received additional treatments such as ifosfamide, carboplatin, etoposide, brentuximab-vedotin, crizotinib, vinorelbine, gemcitabine, procarbazine, prednisolone, dexamethasone, cisplatin, or oxaliplatin. Despite undergoing additional therapies and procedures, the patients' disease did not respond to treatment. [Extracted from the article]

According to a study report from the FDA Adverse Event Reporting System (FAERS), three patients with non-small cell lung cancer (NSCLC) developed hepatitis, fulminant hepatitis, or acute hepatitis while being treated with crizotinib. The patients' ages, sexes, dosages, routes of administration, duration of treatment, and outcomes were not provided. The development of hepatitis, fulminant hepatitis, and acute hepatitis was considered to be a result of crizotinib treatment. [Extracted from the article]

A retrospective study was conducted on 14 patients between 2012 and 2023, and one patient with infant-type hemispheric glioma (IHGs) was described. The patient received treatment with crizotinib, alectinib, lolartinib, and repotrectinib, but unfortunately, the treatments were not effective and the patient died. This case highlights the lack of efficacy of these drugs for IHGs. [Extracted from the article]

A male infant with embryonal rhabdomyosarcoma exhibited lack of efficacy during treatment with multiple drugs. After unsuccessful chemotherapy and radiation therapy, the patient received an off-label treatment with crizotinib, which resulted in a significant reduction in tumor volume. The patient underwent surgery and histological analyses showed no viable tumor cells. This case report highlights the potential efficacy of crizotinib in treating embryonal rhabdomyosarcoma. [Extracted from the article]

A 55-year-old man developed benign fibrous histiocytoma and cutaneous amyloidosis as a result of misusing the drug enfuvirtide for multidrug resistant HIV. The man had been self-administering enfuvirtide injections to his abdomen and thighs, which caused bruising and other side effects. He sought medical attention when a persistent papule appeared on his right thigh. Histopathological analysis confirmed the diagnosis of enfuvirtide-induced benign fibrous histiocytoma and cutaneous amyloidosis. [Extracted from the article]

A 71-year-old woman with non-small cell lung cancer (NSCLC) experienced lack of efficacy during treatment with crizotinib, pemetrexed, cisplatin, and alectinib. She also developed renal and liver cysts while receiving crizotinib. The patient was initially diagnosed with NSCLC in December 2015 and received multiple courses of pemetrexed and cisplatin. However, subsequent CT scans showed metastasis and lack of efficacy. Crizotinib was then initiated, but after three months, the patient developed cystic masses in the kidneys and liver. The cysts were confirmed to be associated with crizotinib and treatment was discontinued. The patient was subsequently prescribed alectinib, but there was no improvement in the lung cancer. [Extracted from the article]

A 48-year-old woman with stage III B lung adenocarcinoma developed an increase in CK and CK-MB levels while being treated with aumolertinib, as well as a first-degree rash reaction while being treated with aumolertinib, furmonertinib, and crizotinib. The woman initially received treatment with aumolertinib and crizotinib, which resulted in a significant reduction in the primary mass and lymph nodes. However, she experienced elevated levels of CK and CK-MB, which were likely side effects of aumolertinib. Another EGFR-TKI, furmonertinib, was then started, and the CK levels gradually returned to normal after discontinuing aumolertinib. The woman currently has stable disease but experienced a first-degree rash reaction to all three medications. [Extracted from the article]

A 49-year-old non-smoking woman with stage IIIB metastatic lung adenocarcinoma exhibited lack of efficacy during treatment with various antineoplastic drugs. After one cycle of pemetrexed and cisplatin, an increase in lung mass size indicated lack of efficacy. She then received crizotinib, but the lung mass continued to increase. Alectinib was also ineffective, and she later received gemcitabine and vinorelbine. Despite treatment, her condition deteriorated, and she eventually died due to the progression of lung adenocarcinoma. [Extracted from the article]

In a study involving 12 patients with MET exon 14 (METex14) mutation non-small cell lung cancer (NSCLC), one patient acquired drug resistance to the type 2 MET tyrosine kinase inhibitor (TKI) glesatinib. The patient initially received glesatinib but developed resistance with amplification of the mutated METex14 allele. As a result, the patient's treatment was switched to the type 1 MET TKI crizotinib. This case highlights the potential for acquired drug resistance in patients with METex14 mutation NSCLC receiving glesatinib. [Extracted from the article]

A retrospective study examined 542 patients with non-small cell lung cancer who were treated with crizotinib or dabrafenib. Two patients developed pneumonitis during their treatment, one with crizotinib and the other with dabrafenib. Both patients had their respective therapies discontinued. The study did not provide information on the ages, sexes, routes of administration, durations of treatment, or outcomes of the patients. [Extracted from the article]

A study involving 51 patients with advanced non-small cell lung cancer found that one patient experienced lack of efficacy during treatment with crizotinib. Despite receiving the medication, the patient's disease continued to progress. The study used an amplicon-based liquid biopsy to detect specific gene fusions. [Extracted from the article]

A woman in her 70s developed grade 3 pneumonitis while being treated with crizotinib and entrectinib for stage IVA non-small-cell lung cancer. The woman experienced symptoms such as pyrexia and increased levels of CRP, and imaging tests revealed lung nodules and mediastinal lymphadenopathy. She was diagnosed with drug-induced lung injury and pneumonitis caused by both crizotinib and entrectinib. Treatment with methylprednisolone and prednisolone was administered, but the symptoms recurred when entrectinib was restarted at a reduced dose. Despite treatment, the woman eventually died as the cancer spread. [Extracted from the article]

A 15-month-old infant boy experienced intermittent mild neutropenia and occasional constipation while being treated with crizotinib for low-grade myopericytoid ovoid sarcoma with ERC1-unaligned anaplastic lymphoma kinase (ALK) fusion. The boy initially had a mass in his right hand and was diagnosed with the sarcoma, which had a novel ALK fusion. After treatment with crizotinib, the tumor regressed significantly, leading to complete resolution. However, the targeted dose of crizotinib was not achieved due to side effects, and the medication was eventually discontinued. The boy did not experience a recurrence of the tumor. [Extracted from the article]

A 45-year-old woman with ROS1-rearranged lung adenocarcinoma stage IV experienced various psychiatric symptoms, including depression, anxiety, paranoia, and tactile hallucinations, while being treated with lorlatinib. She also did not respond to treatment with crizotinib and repotrectinib. After discontinuing lorlatinib, her psychiatric symptoms resolved. She then received treatment with repotrectinib, but her brain lesions continued to progress. Finally, she underwent treatment with carboplatin, pemetrexed, and bevacizumab, which resulted in an excellent response and no evidence of disease in the lungs and brain. [Extracted from the article]

A 75-year-old man with a history of smoking and previous early-stage non-small-cell lung cancer (NSCLC) did not respond to treatment with crizotinib. He presented with mediastinal adenopathy and probable metastatic disease in multiple lymph nodes in the left side of his neck. Despite starting crizotinib in September 2016, there was no positive response after one month of treatment. The man then switched to pemetrexed in November 2016, which effectively delayed disease progression and maintained control for approximately 13 months. [Extracted from the article]

A 49-year-old man experienced lack of efficacy while undergoing treatment for stage IVB right lung adenocarcinoma with pembrolizumab, cisplatin, pemetrexed, docetaxel, and bevacizumab. Additionally, he developed hyperprogression during treatment with pembrolizumab and hyperlipidemia during treatment with lorlatinib for anaplastic lymphoma kinase (ALK)-positive stage IV right lung adenocarcinoma. The article does not provide details about the specific routes, duration of treatments, or outcomes of these reactions. [Extracted from the article]

A retrospective study conducted in Turkey examined the renal side effects of crizotinib, a medication used to treat non-small cell lung cancer (NSCLC). The study included 26 patients with NSCLC, two of whom developed chronic kidney disease or increased levels of creatine and alanine aminotransferase (ALT) while undergoing treatment with crizotinib. The clinical significance of these side effects was also investigated. The study did not provide information on the ages, sexes, routes, and durations of treatment, as well as dosages and outcomes. [Extracted from the article]

An article in Reactions Weekly reports on a case of a woman with ALK positive lung adenocarcinoma who experienced lack of efficacy and acquired resistance to various antineoplastic drugs, including lorlatinib, carboplatin, paclitaxel, bevacizumab, brigatinib, and alectinib. The woman also developed dysgeusia and appetite loss while being treated with crizotinib. The article does not provide specific details about the woman's age or the duration of her treatments. [Extracted from the article]

Author InformationAn event is serious (based on the ICH definition) when the patient outcome is:• * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important eventA 15-year-old boy exhibited acquired resistance following treatment with crizotinib for anaplastic lymphoma kinase-positive large B-cell lymphoma (ALK+ LBCL). Additionally, he exhibited lack of efficacy following treatment with cisplatin, cytarabine and dexamethasone for ALK+ LBCL [not all dosages stated; routes not stated]. [Extracted from the article]

Author InformationAn event is serious (based on the ICH definition) when the patient outcome is:• * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important eventA 73-year-old woman, developed skin toxicity during treatment with erlotinib for non small cell lung cancer. Subsequently, she exhibited lack of efficacy during treatment with osimertinib, dabrafenib and trametinib for non small cell lung cancer [routes and dosages not stated]. [Extracted from the article]

A 20-year-old woman in Iran was diagnosed with epithelioid type inflammatory myofibroblastic sarcoma (EIMS) and underwent surgery. She was then treated with crizotinib, but after 4 months, the tumor recurred and the crizotinib treatment was discontinued due to lack of efficacy. She was then started on chemotherapy with docetaxel and gemcitabine, but there was no response. Unfortunately, after 8 months, she passed away due to EIMS. [Extracted from the article]

Subsequently, PET/CT showed Deauville score of 4 in left cervical and supraclavicular lymph nodes, indicating lack of efficacy. PET/CT after approximately 8 weeks following radiation therapy noted partial response. He then received localized radiation therapy to left cervical lymph nodes and follow-up PET/CT following 3 months revealed near complete response. [Extracted from the article]

Therefore, in 50 patients anaplastic lymphoma kinase inhibitors were discontinued: alectinib (4 patients), ceritinib (2 patients), crizotinib (7 patients) and lorlatinib (17 patients). Additionally, the patients received dexamethasone (8 patients), prednisolone (2 patients) and prednisone (1 patient). The patients, who had NSCLC, received treatment with anaplastic lymphoma kinase inhibitors including alectinib (18 patients), brigatinib (10 patients), ceritinib (12 patients), crizotinib (29 patients) and lorlatinib (26 patients). [Extracted from the article]

Further NGS detected the emergence of ALK L1196M and retention of EML4-ALK and ALK F1174C. To identify the mechanism underlying resistance to crizotinib, ctDNA was analyzed using NGS was performed, which revealed EML4-ALK rearrangement and six ALK point mutations (E1129V, F1174C, F1174L, F1174V, I1171T, and G1269A). Durable clinical response to ALK tyrosine kinase inhibitors in ALK-rearranged non-small cell lung cancer: a case report. [Extracted from the article]

However, she developed treatment related adverse drug reactions including hypercholesterolemia and hypertriglyceridaemia [ I durations of treatments to reactions onsets and outcomes not stated i ]. After 27 months of treatment, CT scan showed disease progression with central nervous system (CNS) metastases in October 2019 (indicating treatment failure to crizotinib). [Extracted from the article]

Despite receiving crizotinib therapy for 7 months, progression of the metastatic NSCLC along with brain metastases was observed indicating lack of efficacy. Despite receiving pemetrexed, docetaxel, ramucirumab, unspecified platinum complexes and selpercatinib therapy, progression of the metastatic NSCLC was observed indicating lack of efficacy. Therefore, she started receiving cyclical treatment with pemetrexed, docetaxel, ramucirumab and unspecified platinum complexes [platinum] doublet therapy. [Extracted from the article]